Evidence map›Paper›PMID 42215865›Full record

ArticleBMC bioinformatics2026

scZGA: a novel model based on ZINB distribution and graph attention for scRNA-seq data clustering.

Yansheng Kan, Yuling Liu, Jiacheng Pan, Ruochen Wang, Chen-Yu Zhang, Zhen Zhou

Abstract read
In one paragraph

Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yansheng Kan *Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China.
Yuling Liu *Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China.
Jiacheng Pan *Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China.
Ruochen WangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China.
Chen-Yu ZhangNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China. cyzhang@nju.edu.cn.
Zhen ZhouNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Sciences, NJU Advanced Institute of Life Sciences (NAILS), Nanjing University, Nanjing, 210023, Jiangsu, China. zhenzhou@nju.edu.cn.

Funding

the CAMS Innovation Fund for Medical Sciences No. CIFMS-2021-I2M-5-015the National Natural Science Foundation of China 91857000, 32022015the "Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NTICB No. 2022HS02008
6 · The paper itself

Abstract

backgroundIdentifying different cell types is a prerequisite step in the analysis of single-cell RNA sequencing (scRNA-seq) data, with clustering being a common technique utilized for this purpose. However, high dropout rates inherent in scRNA-seq data and complex intercellular relationships become main challenges in scRNA-seq data analysis.

resultsTo address these issues, we proposed a novel model based on zero-inflated negative binomial (ZINB) distribution and graph attention network for scRNA-seq data clustering (scZGA). scZGA consists of three key modules. The first module captures the global probabilistic structure using a ZINB model. The second module constructs the graph with Pearson's correlation coefficient, and employs a graph autoencoder with residual connection to learn important neighbor relationships while preserving topological structure information simultaneously. The final module conducts deep clustering through a self-optimizing embedding algorithm.

conclusionsWith these improvements, clustering results show that scZGA consistently achieves higher scores across six scRNA-seq datasets by using evaluation metrics such as normalized mutual information and adjusted rand index.

Indexed as

RNA-SeqSequence Analysis, RNASingle-Cell AnalysisAlgorithmsAutoencoderCluster AnalysisClustering AlgorithmsGraph Neural NetworksSingle-Cell Gene Expression AnalysisClusteringGraph neural networkscRNA-seqZINB autoencoder

Identifiers

PMID42215865
PMCPMC13425930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.